# Myocardial ischaemia following COVID-19: a cardiovascular magnetic resonance study

**Authors:** J. Ranjit Arnold, Jian L. Yeo, Charley A. Budgeon, Simran Shergill, Rachel England, Hunain Shiwani, Jessica Artico, James C. Moon, Miroslawa Gorecka, Giles Roditi, Andrew Morrow, Kenneth Mangion, Mayooran Shanmuganathan, Christopher A. Miller, Amedeo Chiribiri, Mohammed Alzahir, Sara Ramirez, Andrew Lin, Peter P. Swoboda, Adam K. McDiarmid, Robert Sykes, Trisha Singh, Chiara Bucciarelli-Ducci, Dana Dawson, Marianna Fontana, Charlotte Manisty, Thomas A. Treibel, Eylem Levelt, Robin Young, Alex McConnachie, Stefan Neubauer, Stefan K. Piechnik, Rhodri H. Davies, Vanessa M. Ferreira, Marc R. Dweck, Colin Berry, Gerry P. McCann, John P. Greenwood

PMC · DOI: 10.1007/s10554-024-03304-7 · 2024-12-30

## TL;DR

This study found that about 20% of patients hospitalized with COVID-19 and elevated heart markers had heart issues, but these were similar to those in a control group with similar health conditions.

## Contribution

The study is the first to use cardiovascular magnetic resonance to compare myocardial ischaemia in post-COVID-19 patients with matched controls.

## Key findings

- Myocardial ischaemia was present in ~20% of post-COVID-19 patients with elevated troponin.
- There was no significant difference in ischaemia frequency between post-COVID-19 patients and matched controls.
- Ischaemia was not strongly associated with myocardial scar or prior heart disease in these patients.

## Abstract

The pathophysiology of myocardial injury following COVID-19 remains uncertain. COVID-HEART was a prospective, multicentre study utilising cardiovascular magnetic resonance (CMR) to characterise COVID-related myocardial injury. In this pre-specified analysis, the objectives were to examine (1) the frequency of myocardial ischaemia following COVID-19, and (2) the association between ischaemia and myocardial injury. We studied 59 patients hospitalised with COVID-19 and elevated serum troponin (COVID + /troponin + , age 61 ± 11 years) and 37 control subjects without COVID-19 or elevated troponin and similar by age and cardiovascular comorbidities (COVID −/comorbidity + , 64 ± 10 years). Subjects underwent multi-parametric CMR (comprising assessment of ventricular volumes, stress perfusion, T1/T2 mapping and scar). The primary endpoint was the frequency of inducible myocardial ischaemia. Inducible ischaemia was evident in 11 (19%) COVID + /troponin + patients and in 8 (22%) control subjects (p = 0.72). In COVID + /troponin + patients with ischaemia, epicardial coronary disease pattern ischaemia was present in eight patients and microvascular disease pattern, in three patients. There was no significant difference in the frequency of inducible ischaemia in COVID + /troponin + patients with previous myocardial infarction and/or revascularisation compared to those without (2/12 [17%] vs. 9/47 [19%] respectively, p = 0.84), or in those with and without scar (7/27 [26%] vs. 4/32 [13%] respectively, p = 0.19). Myocardial ischaemia was present in ~ 20% of patients recently hospitalised with COVID-19 and with elevated cardiac troponin, but this was not different to matched comorbid controls. This finding coupled with the lack of an association between ischaemia and myocardial scar suggests that coronary artery abnormalities are unlikely to be the predominant mechanism underlying COVID-19 induced myocardial injury.

The online version contains supplementary material available at 10.1007/s10554-024-03304-7.

## Linked entities

- **Diseases:** myocardial infarction (MONDO:0005068), COVID-19 (MONDO:0100096)

## Full-text entities

- **Diseases:** microvascular disease (MESH:D017566), COVID (MESH:D000086382), Myocardial ischaemia (MESH:D009202), coronary disease (MESH:D003327), coronary artery abnormalities (MESH:D003324), myocardial scar (MESH:D002921), ischaemia (MESH:D007511), myocardial infarction (MESH:D009203)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11811239/full.md

---
Source: https://tomesphere.com/paper/PMC11811239